Join the Kidney Health Initiative (KHI) for a mixer focused on the future of Alport syndrome therapies. We’ll share updates from our December 2025 FDA campus meeting, where international partners and regulators came together to advance clinical and surrogate endpoint validation—work that has a significant impact on the entire therapeutic pipeline. This session will highlight […]